^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Adenocarcinoma
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab-actl) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The following regimens recommended added as Other Recommended for adenocarcinoma, large cell, NSCLC NOS….Tremelimumab-actl + durvalumab + carboplatin + albumin-bound paclitaxel...Tremelimumab-actl + durvalumab + (carboplatin or cisplatin) + pemetrexed
    Secondary therapy:
    carboplatin + pemetrexed; cisplatin + pemetrexed; carboplatin + albumin-bound paclitaxel